Nanoparticles in Biotechnology, Drug Development and Drug Delivery
The global market for nanoparticles in biotechnology, drug development and drug delivery was valued at $17.5 billion in 2011 and should reach nearly $21.6 billion in 2012. Total market value is expected to reach $53.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 19.9%.
Current and projected product forecasts during the forecast period of 2012 through 2017 are discussed. New product launches will be discussed. Revenue figure for 2011 are in an actual figures except where actual results have not been reported due to the timing of this report’s release.
The report includes analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs. In this case of pharmaceutical applications, this report does not measure the value of the particles that the particle manufacturer receives. Instead this report includes research dollars invested in designing better particles, or better delivery approaches. Also, the value created through clinical trial success and eventual FDA approval and entrance as a prescription drug, are also included.
Market figures are based on revenues at the manufacturer level and are projected at 2011 dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.
Included in this report are forecasts by product, product category and by company from 2010 through 2017. The study is arranged to offer an overview of existing nanoparticle technology and of drug markets; it is accompanied by nanoproduct, company, geography, and mechanism of action, with forecasts broken down and covered by geographic region or country.
Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis unless specifically noted.
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.